



# IMAGINE...

## Increasing Lab Efficiency and Treating More Patients

AFib is a worldwide epidemic affecting approximately **33 MILLION**<sup>1,2</sup> and on the rise



About **50-70%** of the financial burden of AF is attributable to **HOSPITALIZATION COSTS**<sup>3</sup>



## THE PERCLOSE™ PROSTYLE™ ADVANTAGE

**IMMEDIATE AND DURABLE HEMOSTASIS**



Can be confirmed and challenged on the table<sup>4</sup> while patient is on full-dose anticoagulants.<sup>5</sup>



**NOW AVAILABLE**

for use in common femoral veins with small and large sheaths (5F-24F<sup>4</sup>, Max OD 29F<sup>7</sup>).

AMBULATION IN



**↓ 1.9%**

Low Major Complication Rate<sup>6</sup>

**NO**

Late Recurrences of Bleeding<sup>4</sup>

The use of the Perclose™ ProStyle™ Suture-Mediated Closure and Repair System can help:

**INCREASE**  
EP Lab Efficiency

**MINIMIZE**  
Avoidable Costs

**ENHANCE**  
Patient Experience



Faster Hemostasis and Ambulation



Optimization of Clinical Resources



Faster Patient Turnover

- Monitoring
- Re-Bleeding
- In-Patient Stay
- Pain Medication
- Foley Catheter UTI's
- Access-Site Complications



Shorter Bed Rest and Hospital Stay



Less Pain Medication



Less Need For Foley Catheter

SOURCE: S. Verma. Adopting a Strategy of Early Ambulation and Same-Day Discharge for Atrial Fibrillation Ablation Cases - EP Lab Digest - May 2019.

## That's Worth Thinking About.

Information contained herein for DISTRIBUTION within Canada only.

©2023 Abbott. All Rights Reserved MAT-2312128 V1.0

**Perclose™ ProStyle™**  
Suture-Mediated Closure and Repair System

1. Chugh SS, et al. Circulation 2014 Worldwide Epidemiology of AF - A Global Burden of Disease Study 2010.
2. Rahman F, et al. Nat. Rev. *Cardiol.* 11, 639–654 (2014).
3. Patel NJ, et al. Global rising trends of atrial fibrillation - a major public health concern. June 2018.
4. As per Instructions for Use (IFU), patients may be ambulated 2 hours after the Perclose ProGlide SMC system procedures using 5F-8F sheaths. For sheaths > 8F, ambulation time is at the physician's discretion. Perclose ProGlide SMC System – Instructions for Use. Data on file at Abbott.
5. Mahavdaven VS, et al. Pre-closure of femoral venous access sites used for large-sized sheath insertion with the Perclose device in adults undergoing cardiac intervention.
6. Kar S, et al. The Use of the Perclose ProGlide Suture-Mediated Closure (SMC) Device for Venous Access-Site Closure up to 24F Sheaths. CRT 2018.
7. Max. OD 29F/0.378 inches/9.59 mm. Tests performed by and data on file at Abbott.

CAUTION: Certain configurations of the devices within may not have been licensed in accordance with Canadian law. Contact your local sales representative for the regulatory status of the device(s) in Canada. This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [eifu.abbottvascular.com](http://eifu.abbottvascular.com) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events as applicable to Canada. This material is intended for use with healthcare professional only.

**Information contained herein for DISTRIBUTION within Canada only.**

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

**Abbott**

6975 Creditview Road Unit 1 Mississauga, Ontario L5N8E9 Canada Tel: 1-866-552-5753

<sup>TM</sup> Indicates a trademark of the Abbott Group of Companies.

<sup>#</sup> Indicates a third-party trademark, which is property of its respective owner.

[www.cardiovascular.abbott](http://www.cardiovascular.abbott)

©2023 Abbott. All Rights Reserved MAT-2312128 V1.0

